2 stories in this blend

Moderna used artificial intelligence to analyze genetic data from patient tumors and identify targets that best provoke an immune response. When combined with an existing drug, the personalized mRNA vaccine significantly reduced melanoma recurrence during a major clinical trial.

An automated analysis tool called CenSegNet evaluated more than 330,000 cellular components from 127 patient samples. University of Southampton researchers discovered that what was previously considered a single cellular anomaly actually splits into two separate defects that act independently and relate to tumor aggression.